World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
39845
World Ranking
17351
National Ranking
8694

Overview

Charles D. Blanke is affiliated with Oregon Health & Science University in the United States and has produced a substantial body of work in the field of medicine, particularly focusing on oncology and cancer research. Their research contributions span multiple subfields including pulmonary and respiratory medicine, pathology and forensic medicine, and surgery.

The scientist's research covers topics related to colorectal cancer treatments and studies, genetic factors in colorectal cancer, cancer genomics and diagnostics, cancer immunotherapy and biomarkers, gastric cancer management and outcomes, economic and financial impacts of cancer, and peptidase inhibition and analysis.

Frequent coauthors in their publications include Megan Othus, Young Kwang Chae, Razelle Kurzrock, Sandip Pravin Patel, and Elad Sharon, each collaborating on numerous projects.

Charles D. Blanke has published extensively in high-impact venues such as:

  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Cancer Research
  • Cancer
  • JAMA Network Open

Notable recent publications include:

  • A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors (2020), Clinical Cancer Research
  • Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) (2021), Journal for ImmunoTherapy of Cancer
  • Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor (2023), Journal of Clinical Oncology
  • Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer (2021), JAMA
  • Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol (2020), The Lancet Oncology

Best Publications

  • Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

    George Daniel Demetri;Margaret von Mehren;Charles D. Blanke;Annick Diane Van Den Abbeele

  • Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

    Leonard B. Saltz;John V. Cox;Charles Blanke;Lee S. Rosen

  • Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

    Michael C. Heinrich;Christopher L. Corless;George D. Demetri;Charles D. Blanke

  • Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

    Ronald P. DeMatteo;Karla V. Ballman;Cristina R. Antonescu;Robert G. Maki

  • Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

    Charles D. Blanke;Cathryn Rankin;George D. Demetri;Christopher W. Ryan

  • Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

    Charles D Blanke;George D Demetri;Margaret von Mehren;Michael C Heinrich

  • NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

    George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay

  • Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors

    Michael C. Heinrich;Christopher L. Corless;Charles D. Blanke;George D. Demetri

  • Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection

    Stephen R. Smalley;Jacqueline K. Benedetti;Daniel G. Haller;Scott A. Hundahl

  • Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

    Alan P. Venook;Donna Niedzwiecki;Heinz Josef Lenz;Federico Innocenti

  • Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies

    Michael C. Heinrich;Charles D. Blanke;Brian J. Druker;Christopher L. Corless

  • Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

    Philip A. Philip;Jacqueline Benedetti;Christopher L. Corless;Ralph Wong

  • Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

    Michael C. Heinrich;Kouros Owzar;Christopher L. Corless;Donna Hollis

  • Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Daniel J. Sargent;Harry S. Wieand;Daniel G. Haller;Richard Gray

  • Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

    Burton L. Eisenberg;Jonathan Harris;Charles D. Blanke;George D. Demetri

  • CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).

    Alan P. Venook;Donna Niedzwiecki;Heinz-Josef Lenz;Federico Innocenti

  • Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

    George D. Demetri;Yanfeng Wang;Elisabeth Wehrle;Amy Racine

  • Phase II Trial of Erlotinib in Gastroesophageal Junction and Gastric Adenocarcinomas: SWOG 0127

    Tomislav Dragovich;Sheryl McCoy;Cecilia M. Fenoglio-Preiser;Jiang Wang

  • SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

    Edgar Ben-Josef;Katherine A. Guthrie;Anthony B. El-Khoueiry;Christopher L. Corless

  • Impact of primary (1{o}) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

    Alan P. Venook;Donna Niedzwiecki;Federico Innocenti;Briant Fruth

Frequent Co-Authors

Alan P. Venook
Alan P. Venook University of California, San Francisco
Heinz-Josef Lenz
Heinz-Josef Lenz University of Southern California
Donna Niedzwiecki
Donna Niedzwiecki Duke University
Richard M. Goldberg
Richard M. Goldberg West Virginia University
Federico Innocenti
Federico Innocenti University of North Carolina at Chapel Hill
Howard S. Hochster
Howard S. Hochster Yale University
Monica M. Bertagnolli
Monica M. Bertagnolli Brigham and Women's Hospital
Robert J. Mayer
Robert J. Mayer Dana-Farber Cancer Institute
George D. Demetri
George D. Demetri Dana-Farber Cancer Institute
Jeffrey A. Meyerhardt
Jeffrey A. Meyerhardt Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring a medical career in the USA, it’s worth considering alternative online programs in healthcare. These pathways offer flexible and accessible entry points for a variety of professions, whether you’re interested in clinical care, administration, or health education.

Nursing remains a popular and rewarding field. For those looking to avoid lengthy prerequisite tests, some colleges now offer nursing schools that don't require teas, making entry more straightforward.

If leadership or management appeals to you, an accelerated healthcare administration degree can help you quickly enter the business side of healthcare.

Registered nurses can advance their practice and move toward specialized roles with asn to fnp programs, bridging the gap between an associate degree and a nurse practitioner license.

Those with a passion for nutrition science can launch or elevate their careers through an online degree in nutrition. This area supports roles in wellness, dietetics, and public health.

Best Scientists Citing Charles D. Blanke

Trending Scientists

Recently Published Articles